Difference between revisions of "Team:Evry/Project/Chassis"

Line 52: Line 52:
  
 
<p class="text-justify"><strong>References</strong></p>
 
<p class="text-justify"><strong>References</strong></p>
 +
<p class="text-justify">8. J Banchereau & R M. Steinman, Dendritic cells and the control of immunity, Nature 392, 245-252 (19 March 1998) | doi:10.1038/32588</p>
 +
<p class="text-justify">9. Wang Yan, Development of anti-tumor immunotherapy mediated by type III secretion system- based live attenuated bacterial vectors. Human health and pathology. Université de Grenoble, 2012. French. <NNT : 2012GRENS010, tel-00767285></p>
 +
<p class="text-justify">10. Epaulard O, Toussaint B,  Quenee L, Derouazi M, Bosco N, Villiers C, Le Berre R, Guery B, Filopon D, Crombez L, N. Marche P, and Polack B, Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector, Mol Ther, doi:10.1016/j.ymthe.2006.06.01</p>
 +
<p class="text-justify">11. Chauchet Xavier, Immunothérapie anti-tumorale active par vecteur bactérien vivant attenué : mise au point de l’approche vaccinale ”killed but metabolically active”. Pharmaceutical sciences. 2013. <dumas-00822794></p>
 +
<p class="text-justify">12. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009 Jun 19;27(30):3975-83. doi: 10.1016/j.vaccine.2009.04.041</p>
 +
<p class="text-justify">13. KJ Radford, DE Higgins, S Pasquini, EJ Cheadle, L Carta, AM Jackson, NR Lemoine and G Vassaux, A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy, Nature Gene Therapy (2002) 9, 1455–1463</p>
 +
<p class="text-justify">14. Munson S, J Parker, TH King, Y Lio, V Kelley, Z Guo, V Borges, and A Franzusoff, Coupling innate and adaptive immunity with yeast-based cancer immunotherapy, 2008, Cancer Vaccines and Tumor Immunity, New York, p. 131-149</p>
 +
<p class="text-justify">15. Underhill D, Macrophage recognition of zymosan particles. JEndotoxin, Res 9: 176-180. M. 2003</p>
 +
<p class="text-justify">16. Tada H, E. Nemoto, H Shimauchi, T Watanabe, T Mikami, T Matsumoto, N Ohno, H Tamura, K Shibata, S Akashi, K Miyake, S Sugawara, and H Takada, Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4- dependent manner. MicrobiolImmunol, 2002, 46: 503-512</p>
 +
<p class="text-justify">17. Sheng, K-C, DS Pouniotis, MD Wright, CK Tang, E Lazoura, G A Pietersz, and V. Apostolopoulos, Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 2006, 118: 372-383</p>
 +
<p class="text-justify">18. Stubbs AC, KS Martin, C Coeshott, SV Skaates, DR Kuritzkes, D Bellgrau, A Franzusoff, RC Duke, and CC Wilson, Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity, 2001, NatMed 7: 625- 629</p>
 +
<p class="text-justify">19. Lu Y, D Bellgrau, LD Dwyer-Nield, AM Malkinson, RC Duke, TC Rodell, and A Franzusoff, Mutation-selective tumor remission with Ras-targeted, whole yeast- based immunotherapy, 2004, CancerRes 64: 5084-5088</p>
 +
 +
<p class="text-justify">20. Riemann H, J Takao, YG Shellman, WA Hines, CK Edwards, DA Norris and M Fujita, Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1, 2007, ExperimentalDermatology, 16: 814-822</p>
 +
<p class="text-justify">21. Franzusoff A, RC Duke, TH King, Y Lu and TC Rodell, Yeasts encoding tumour antigens in cancer immunotherapy, 2005. Expert Opinion on Biological Therapy 5: 565- 575</p>
 +
<p class="text-justify">22. Howland SW, Wittrup KD, Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol 2008;180:1576–1583</p>
 +
<p class="text-justify">23. Anjuere F, Martin P, Ferrero I, Fraga ML, del Hoyo GM, Wright N, Ardavin C, Definition of dendritic cell subpopulations present in the spleen, Peyer’s patches, lymph nodes, and skin of the mouse, 1999, Blood 93, 590–598</p>
 +
<p class="text-justify">24. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii SI, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM, In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. 2004, J. Exp. Med. 199, 815–824</p>
 +
<p class="text-justify">25. Demangel C, J Zhou, A BH Choo, G Shoebridge, GM. Halliday, WJ Britton, Single chain antibody fragments for the selective targeting of antigens to dendritic cells, 2005 May, Mol Immunol. 42(8):979-85</p>
 +
<p class="text-justify">26. Petrovsky N, Aguilar JC, Vaccine adjuvants: current state and future trends Immunol Cell Biol. 2004;82:488–496</p>
 +
  
  

Revision as of 21:17, 18 September 2015

Scroll to top To top